Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology has announced a voluntary on-market share repurchase plan, with the board resolving to buy back shares worth up to HK$20 million. The decision reflects the company’s confidence in its business prospects and aims to enhance shareholder value, though the execution of the repurchase will depend on market conditions.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on developing innovative oncology therapies and has a market presence in Hong Kong.
Average Trading Volume: 4,256,836
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.72B
See more insights into 9966 stock on TipRanks’ Stock Analysis page.